Tuesday, November 17, 2026
RSS


← All Stories

Pharmaceutical

Intellia Therapeutics Advances with FDA Priority Review for Groundbreaking CRISPR Therapy

Intellia Therapeutics secures FDA Priority Review for its CRISPR therapy, potentially transforming the treatment landscape for hereditary an…

Sep 8, 2026
Pharmaceutical

Sernova and Seraxis Merge to Form BetaNova Biotherapeutics: A New Player in Type 1 Diabetes Treatment

Sernova and Seraxis merge to create BetaNova, a company poised to innovate in Type 1 diabetes treatment.

Sep 8, 2026
Pharmaceutical

Merck-Moderna mRNA Cancer Vaccine Hits Phase 3 Melanoma Endpoints, Boosting Both Stocks' Oncology Pipelines

The INTerpath-001 Phase 3 trial of intismeran autogene plus KEYTRUDA met co-primary endpoints in melanoma, de-risking the mRNA oncology plat…

Sep 7, 2026
Pharmaceutical

Merck and Moderna's mRNA Cancer Vaccine Hits Phase 3 Milestone — What It Means for MRK and MRNA Investors

Merck and Moderna's Phase 3 INTerpath-001 trial met both primary endpoints for melanoma, validating mRNA neoantigen technology and opening m…

Sep 6, 2026
Pharmaceutical

Royalty Pharma Shares Under Pressure as Novartis' Pelacarsen Phase 3 HORIZON Trial Disappoints

RPRX's royalty stake in pelacarsen suffers as Novartis' Phase 3 cardiovascular outcomes trial misses key endpoints, pressuring net present v…

Sep 5, 2026
Pharmaceutical

Merck and Moderna's mRNA Cancer Vaccine Scores Phase 3 Win — What It Means for MRK and MRNA Investors

The Phase 3 INTerpath-001 trial of Moderna's personalized mRNA cancer vaccine plus Merck's Keytruda met both co-primary endpoints in high-ri…

Sep 5, 2026
Pharmaceutical

Moderna and Merck's mRNA Cancer Vaccine Trial: A Turning Point for Biotech Investors

The Phase 3 INTerpath-001 trial results could reshape oncology market dynamics for Moderna and Merck, opening new revenue streams.

Sep 4, 2026
Pharmaceutical

Merck and Moderna's mRNA Vaccine Triumphs in Melanoma Phase 3 Trials

Merck and Moderna's Phase 3 trial results demonstrate significant advancements in melanoma treatment, impacting stock performance and oncolo…

Sep 4, 2026
Pharmaceutical

Ionis Pharmaceuticals Secures FDA Approval for Groundbreaking Zanvastro Treatment

Ionis Pharmaceuticals' Zanvastro receives FDA approval, marking a significant milestone in the treatment of Alexander disease.

Sep 4, 2026
Pharmaceutical

AbbVie Expands Immunology Pipeline with $11 Billion Acquisition of Apogee Therapeutics

AbbVie makes a bold move, acquiring Apogee Therapeutics for $11 billion, signaling a strategic push in immunology.

Sep 3, 2026
Pharmaceutical

Moderna's 177% Surge: The Successful Phase 3 Trial That Could Transform Oncology

Moderna's recent Phase 3 trial success has triggered a 177% stock surge, signaling a potential new era in oncology investment.

Sep 3, 2026
Pharmaceutical

Ultragenyx's Dramatic Stock Plunge: What It Means for Rare Disease Biotech Investors

Ultragenyx's stock plummeted 44.7% following the failure of a pivotal trial, raising questions for biotech investors.

Sep 3, 2026